Skip to content

Randomized Controlled Clinical Study of Yijinjing in the Treatment of Sarcopenia

Randomized Controlled Clinical Study of Yijinjing in the Treatment of Sarcopenia: A Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000434
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Experimental group:Yijinjing training

Sponsors

Wangjing Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets Western diagnostic criteria for sarcopenia ; 2. Aged 50-75 years, gender non-specific; 3. Capable of self-care, able to walk daily without assistive devices (e.g., crutches); 4. Voluntary participation with signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary sarcopenia (caused by malignancy, severe hepatic/renal dysfunction, etc.); 2. Severe cardiovascular diseases, wasting diseases, infections, or severe osteoporosis; 3. Cognitive or mental disorders (e.g., Alzheimer's) preventing cooperation; 4. Inability to perform exercise training (joint deformity, bedridden, fractures); 5. Use of hormones or muscle relaxants within the past month; 6. Participation in other interventional trials within the past month.

Design outcomes

Primary

MeasureTime frame
Short Physical Performance Battery (SPPB) Score;

Secondary

MeasureTime frame
4-meter Gait Speed;Timed Up and Go Test ;Handgrip Strength;Performance-Oriented Mobility Assessment;Body Composition;Fatigue, Resistance, Ambulation, Illnesses, Loss of Weight Scale;Activities of Daily Living;Geriatric Depression Scale;Mini-Nutritional Assessment-short Form;Pittsburgh Sleep Quality Index;12-Item Short Form Health Survey;Serum Biomarkers;

Countries

China

Contacts

Public ContactLiu Zhize

Wangjing Hospital, China Academy of Chinese Medical Sciences

bucm_liuzhize@163.com17601080830

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026